Shots:Halozyme Therapeutics has entered into a definitive agreement to acquire Elektrofi, incl. its Hypercon technology, which enables biologic formulations at concentrations of 400-500mg/mlAs per the deal, Elektrofi will receive $750M upfront, with up to three $50M milestone payments contingent on regulatory approvals of three separate Hypercon products; closing expected in Q4’25As a result…
Shots: Fragmented workflows continue to be a major roadblock in the healthcare ecosystem, causing unnecessary delays in care delivery Automated solutions help bridge the gaps resulting from disjointed workflows and expedite prior authorization, pharmacy routing, and patient onboarding Colin Banas, CMO at DrFirst, joins PharmaShots in a discussion highlighting the company’s recent acquisition of Myndshft…
Shots: Supreme Group recently announced its 8th acquisition, adding Nimble Works and Vital Works to its portfolio, strengthening its presence in healthcare marketing and communications The acquisition brings together Nimble Works’ insight-driven creative strengths and Vital Works’ performance-focused digital expertise to navigate complex healthcare domains and accelerate data-driven growth marketing Tom Donnelly, CEO of Supreme…
Shots: Intas Pharmaceuticals, through its Accord subsidiaries, has completed the acquisition of Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv), a biosimilar of Neulasta With the acquisition, Accord BioPharma, Intas’ U.S. specialty arm, continues Udenyca commercialization, offering patient-friendly administration options autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS) Udenyca is a leukocyte growth factor used to reduce infection risk in…
Shots:Bain Capital has signed to acquire Mitsubishi Tanabe Pharma in a carve-out deal from Mitsubishi Chemical Group at ~510 billion JPY (3.3 billion USD), is led by Bain Capital’s Private Equity teams in Asia, North America, and its Life Sciences team.
The transaction is expected to close in Q3’25, pending regulatory approval, shareholder…
Shots: Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab With this acquisition, Genmab…
Shots: Sticking to M&A and licensing agreements can be really challenging, especially when dealing with stringent antitrust laws and evolving regulatory challenges. In such adverse scenarios, the rational and right step seems to be nullifying the existing deals.In 2023, the termination of the deal between Janssen and Arrowhead remained the talk of the town…
Shots: Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline The acquisition provides Shionogi exclusive development, manufacturing,…
Shots:In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the monthEnbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseasesPharmaShots…
Shots:Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platformMark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…

